Forma Stock Analysis

FMTX -  USA Stock  

USD 25.99  0.64  2.52%

The current Forma Therapeutics price slide could raise concerns from investors as the firm it trading at a share price of 25.99 on very low momentum in volume. The company executives were unable to exploit market volatilities in May. However, diversifying your overall positions with Forma Therapeutics Holdings can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.58. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Forma Therapeutics partners.
Please check Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Forma Therapeutics stock analysis report makes it easy to digest most publicly released information about Forma Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Forma stock analysis module also helps to analyze the Forma Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Forma Stock Analysis Notes

About 84.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. Forma Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people. To learn more about Forma Therapeutics Holdings call the company at 617 679 1970 or check out http://www.formatherapeutics.com.

Forma Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Forma Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Forma Therapeutics Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Forma Therapeutics generates negative expected return over the last 90 days
Forma Therapeutics has high historical volatility and very poor performance
Forma Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 7.44 M. Net Loss for the year was (74.15 M) with loss before overhead, payroll, taxes, and interest of (93.37 M).
Forma Therapeutics Holdings currently holds about 633.05 M in cash with (95.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.38.
Over 84.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: Forma Therapeutics Holdings Inc gains 4.6220 percent for June 17 - Equities.com

Forma Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Forma Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Forma Therapeutics Holdings backward and forwards among themselves. Forma Therapeutics' institutional investor refers to the entity that pools money to purchase Forma Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ra Capital Management LpCommon SharesM252.5 M
Fmr LlcCommon SharesM139.3 M
Cormorant Asset Management LpCommon Shares4.7 M132.3 M
Blackrock IncCommon Shares3.3 M92.2 M
Vanguard Group IncCommon Shares2.2 M61.4 M
Baker Bros Advisors LpCommon SharesM56.7 M
State Street CorpCommon Shares1.9 M52.4 M
Note, although Forma Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Forma Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.26 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Forma Therapeutics's market, we take the total number of its shares issued and multiply it by Forma Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (17.96) % which means that it has lost $17.96 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (17.5) %, meaning that it created substantial loss on money invested by shareholders. Forma Therapeutics management efficiency ratios could be used to measure how well forma therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 19th of June, Forma Therapeutics shows the mean deviation of 3.2, and Coefficient Of Variation of (1,327). Forma Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Forma Therapeutics Holdings, which can be compared to its rivals. Please confirm Forma Therapeutics variance and potential upside to decide if Forma Therapeutics is priced favorably, providing market reflects its regular price of 25.99 per share. Given that Forma Therapeutics has jensen alpha of (0.35), we urge you to verify Forma Therapeutics Holdings's prevailing market performance to make sure the company can sustain itself at a future point.

Forma Therapeutics Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Forma Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forma Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forma Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Forma Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bishop John E few days ago via Macroaxis 
Acquisition by Bishop John E of 67000 shares of Forma Therapeutics subject to Rule 16b-3
Ra Capital Management Lp over two months ago via Macroaxis 
Forma Therapeutics exotic insider transaction detected
Kelly Patrick F over three months ago via Macroaxis 
Acquisition by Kelly Patrick F of 50250 shares of Forma Therapeutics subject to Rule 16b-3
Vickers Selwyn M Md over three months ago via Macroaxis 
Acquisition by Vickers Selwyn M Md of 25000 shares of Forma Therapeutics subject to Rule 16b-3
Potts Jeannette over three months ago via Macroaxis 
Exercise or conversion by Potts Jeannette of 3400 shares of Forma Therapeutics subject to Rule 16b-3
Hall Steven Edward over six months ago via Macroaxis 
Conversion by Hall Steven Edward of 3178630 shares of Forma Therapeutics
Wiggans Thomas G over six months ago via Macroaxis 
Acquisition by Wiggans Thomas G of 25000 shares of Forma Therapeutics subject to Rule 16b-3
Frederick Wayne Ai over six months ago via Macroaxis 
Acquisition by Frederick Wayne Ai of 25000 shares of Forma Therapeutics subject to Rule 16b-3
Wellington Biomedical Innovation Master Investors Cayman I Lp over six months ago via Macroaxis 
Conversion by Wellington Biomedical Innovation Master Investors Cayman I Lp of 5359344 shares of Forma Therapeutics
Kelly Patrick F over six months ago via Macroaxis 
Sale by Kelly Patrick F of 40911 shares of Forma Therapeutics
Kelly Patrick F over six months ago via Macroaxis 
Acquisition by Kelly Patrick F of 116890 shares of Forma Therapeutics subject to Rule 16b-3

Forma Therapeutics Technical and Predictive Indicators

Forma Therapeutics Forecast Models

Forma Therapeutics time-series forecasting models is one of many Forma Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Forma Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Forma Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Forma Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Forma shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Forma Therapeutics. By using and applying Forma Stock analysis, traders can create a robust methodology for identifying Forma entry and exit points for their positions.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. Forma Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Forma Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module
Please check Investing Opportunities. Note that the Forma Therapeutics information on this page should be used as a complementary analysis to other Forma Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively-traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Forma Therapeutics Stock analysis

When running Forma Therapeutics price analysis, check to measure Forma Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forma Therapeutics is operating at the current time. Most of Forma Therapeutics' value examination focuses on studying past and present price action to predict the probability of Forma Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Forma Therapeutics' price. Additionally, you may evaluate how the addition of Forma Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
The market value of Forma Therapeutics is measured differently than its book value, which is the value of Forma that is recorded on the company's balance sheet. Investors also form their own opinion of Forma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Forma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Forma Therapeutics' market value can be influenced by many factors that don't directly affect Forma Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Forma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Forma Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Forma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.